{"id":"athena-car-t","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Cytokine release syndrome"},{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"}]},"_chembl":{"chemblId":"CHEMBL106174","moleculeType":"Protein","molecularWeight":"635.76"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"A type of immunotherapy that uses genetically modified T cells to recognize and attack cancer cells expressing CD19.","oneSentence":"CAR-T cell therapy targeting CD19","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T04:55:55.698Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell acute lymphoblastic leukemia"},{"name":"Relapsed or refractory diffuse large B-cell lymphoma"}]},"trialDetails":[{"nctId":"NCT06084884","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-12-14","conditions":"Hepatocellular Carcinoma","enrollment":94},{"nctId":"NCT06014073","phase":"PHASE1, PHASE2","title":"TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2023-09-06","conditions":"Non Hodgkin's Lymphoma","enrollment":30},{"nctId":"NCT06373991","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus","status":"NOT_YET_RECRUITING","sponsor":"EdiGene Inc.","startDate":"2024-07-24","conditions":"Lupus Erythematosus, Systemic","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ET-901"],"phase":"phase_1","status":"active","brandName":"ATHENA CAR-T","genericName":"ATHENA CAR-T","companyName":"EdiGene Inc.","companyId":"edigene-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CAR-T cell therapy targeting CD19 Used for Relapsed or refractory B-cell acute lymphoblastic leukemia, Relapsed or refractory diffuse large B-cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}